Share
Will Kane
Uniquity Bio, a clinical-stage drug development company specializing in immunology and inflammation and backed by Blackstone Life Sciences, has appointed Will Kane as its new President and Chief Executive Officer.
Kane will spearhead the company’s strategic direction and growth, guiding its lead asset, solrikitug, through the final stages of three ongoing Phase II trials and preparing for a rapid transition into Phase III.
Bringing over 30 years of biopharmaceutical leadership experience, Kane has a proven record of building high-performing teams, driving transformational change, and delivering strong business results across multiple therapeutic areas. He succeeds Brian Lortie, co-founder and former CEO, who stepped down in June 2025.
Before joining Uniquity Bio, Kane served as President and Chief Commercial Officer at Anthos Therapeutics, recently acquired by Novartis, and has held senior leadership positions at Karuna Therapeutics, BioXcel Therapeutics, Allergan, and Pfizer.
